Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jubilant Stock Holding Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Intimation of Schedule of Analysts / Institutional Investors Meetings by the Company's wholly-owned subsidiary, Jubilant Pharma Limited, Singapore
Jubilant Life Sciences Ltd has informed BSE regarding "Intimation of Schedule of Analysts / Institutional Investors Meetings by our wholly-owned subsidiary, Jubilant Pharma Limited, Singapore". Updates on Subsidiary
Jubilant Life Sciences Ltd has informed BSE that :- the Company have been informed that the Board of Directors of Company's material wholly-owned subsidiary, Jubilant Pharma Limited ("JPL") has, at its meeting held on September 23, 2016, approved the proposal to launch a benchmark offering of unsecured high yield bonds (the Notes) outside India by JPL, under Regulation S of the US Securities Act. The Notes are proposed to be listed on the Singapore Exchange Securities Trading Limited. Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Jubilant Life Sciences Ltd has informed BSE regarding the details of Voting results at the 38th Annual General Meeting (AGM) of the Company held on August 30, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Buy Jubilant Life Sciences Ltd., target Rs 575.0 : Chandan Taparia
Buy Jubilant Life Sciences Ltd. at a price target of Rs 575.0 and a stop loss at Rs 515.0 from entry point Outcome of AGM
Jubilant Life Sciences Ltd has informed BSE that the 38th Annual General Meeting (AGM) of the Company was held on August 30, 2016. Exercise of ESOP Options
Jubilant Life Sciences Ltd has informed BSE that 1,400 options under Jubilant Employees Stock Option Plan 2005 (Plan 2005") and 12,429 options under JLL Employees Stock Option Plan 2011 (Plan 2011") have been exercised by the option holders.Pursuant to the terms of Plan 2005 and Plan 2011, the Nomination, Remuneration and Compensation Committee of the Company (the Committee") has approved transfer of 19,429 equity shares of Re. 1 each... Jubilant Life Sciences receives ANDA approval for Felodipine ER Tablets
Jubilant Life Sciences Ltd has submitted to BSE a copy of Press Release dated August 24, 2016 titled 'Jubilant Life Sciences receives ANDA approval for Felodipine ER Tablets' Jubilant Life receives US FDA approval for hypertension drug telmisartan
The approved product - telmisartan tablet - is a generic version of Boehringer Ingelheim Pharmaceuticals' Micardis tablet Jubilant Life Sciences receives ANDA approval for Telmisartan Tablets
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated August 24, 2016 titled "Jubilant Life Sciences receives ANDA approval for Telmisartan Tablets".